DIHYDROXY OXALIPLATIN-PT(IV)

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H14N2.C2O4.Pt.2HO
Molecular Weight	431.306
Optical Activity	UNSPECIFIED
Additional Stereochemistry	Yes
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0
Stereo Comments	SQUARE PLANAR, CIS-

SHOW SMILES / InChI

Structure of DIHYDROXY OXALIPLATIN-PT(IV)

SMILES

[OH-].[OH-].[Pt+4].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N

InChI

InChIKey=CRUOOYJLGQUXMM-NDSUJOINSA-J

InChI=1S/C6H14N2.C2H2O4.2H2O.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;;;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);2*1H2;/q;;;;+4/p-4/t5-,6-;;;;/m1..../s1

HIDE SMILES / InChI

Molecular Formula	C2O4
Molecular Weight	88.019
Charge	-2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H14N2
Molecular Weight	114.1888
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Pt
Molecular Weight	195.084
Charge	4
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. Ormaplatin showed marked antitumor activity both in vitro and vivo. The severe, cumulative and irreversible peripheral neurotoxicity observed in phase I studies resulted in termination of further clinical development of ormaplatin.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282	Binding Agent 1,076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609	Primary		Phase I 438	Unknown

C_max

Value	Dose	Analyte	Population
0.576 mg/L	78 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
0.78 mg/L	98 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
0.995 mg/L	123 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
6.62 mg × h/L	78 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
4.37 mg × h/L	98 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
8.05 mg × h/L	123 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
16.2 min	78 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
11.9 min	98 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
10.5 min	123 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens

F_unbound

Value	Dose	Analyte	Population
30%	78 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
30%	98 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens
30%	123 mg/m² single, intravenous	PLATINUM (IV) ION plasma	Homo sapiens

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT2 434

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
OCT2 434	substrate 4,014	yes

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChemIDplus	62816982	https://chem.nlm.nih.gov/chemidplus/id/0062816982
EPA DSSTox	DTXSID50897225	https://comptox.epa.gov/dashboard/DTXSID50897225

Showing 1 to 2 of 2 entries

Previous1Next

PubMed

PubMed

Title	Date	PubMed
No data available in table

Sample Use Guides

In Vivo Use Guide

A phase I trial of ormaplatin administered as a 1-h infusion every 4 weeks was performed. Forty-one patients received 101 cycles of drug over the dose range 4-128 mg/m2.

Route of Administration: Intravenous

In Vitro Use Guide

10 uM tetraplatin (ormaplatin) is cytotoxic for L1210 leukemia cells

Substance Class	Chemical
Record UNII	AXA37HSS7Z
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

((1R-TRANS-(1,2-CYCLOHEXANEDIAMINE-N,N'))-TRANS-DIHYDROXIDO-(OXALATO(2-)-O,O')PLATINUM(IV))

Preferred Name

English

DIHYDROXY OXALIPLATIN-PT(IV)

Common Name

English

(OC-6-33)-((1R,2R)-CYCLOHEXANE-1,2-DIAMINE.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)DIHYDROXYPLATINUM

Systematic Name

English

OXALIPLATIN RELATED COMPOUND C

Common Name

English

OXALIPLATIN IMPURITY C [EP IMPURITY]

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

CAS

111321-67-6

PRIMARY

EPA CompTox

DTXSID60747681

PRIMARY

FDA UNII

AXA37HSS7Z

PRIMARY

SMS_ID

300000053263

PRIMARY

PUBCHEM

129011603

PRIMARY

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					04ZR38536J

OXALIPLATIN

PARENT -> IMPURITY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

Sample Use Guides

C_max

T_1/2

F_unbound